Description
ZLN005 increases expression of PPAR-γ coactivator-1α (PGC-1α), exhibiting anti-diabetic activity. In animal models of diabetes, this compound increases activation of AMPK, stimulates fat oxidation, and improves glucose tolerance and insulin sensitivity.